The impact of a conjugate pneumcoccal vaccine (Prevenar) on the aetiology of childhood pneumonia in the North East

Trial Profile

The impact of a conjugate pneumcoccal vaccine (Prevenar) on the aetiology of childhood pneumonia in the North East

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections; Pneumonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2011 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 10 Aug 2011 United Kingdom Clinical Research Network reports accrual to date changed from 71% to 76%.
    • 11 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top